Benzinga | Dec 1, 2021 08:12AM EST

Teva Pharma Highlights Launch Of Authorized Generic Epiduo Forte Gel In US

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of an authorized generic of Epiduo(r)1 Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the United States.

Adapalene and benzoyl peroxide gel 0.3%/2.5% is a topical prescription medicine used to treat acne vulgaris.

"The launch of our first-to-market authorized generic version of Epiduo(r) Forte Gel in the U.S. provides patients with another important treatment option," said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA. "Continuing to advance and launch much-needed generic drugs is critical to ensuring access to quality medicines to everyone who needs them."

With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market, and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the U.S. Currently, 1 in 11 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Epiduo(r) Forte Gel had annual sales of $253 million in the U.S., according to IQVIA data, as of September 2021.